P8 HOFHERR - Social Media - Ansgar Büngener, Geschäftsführer medienmanufacturP8 Marketing
„Das Social Web hat das Marketing revolutioniert“ so Ansgar Büngener. „Es können heute weltweit 2 Milliarden Internet-Nutzer erreicht werden, die Verbreitung erfolgt in Echtzeit und man kann mit jedem in den Dialog treten.“ Der Schlüssel für einen erfolgreichen Auftritt im Web 2.0 ist Authentizität, Ehrlichkeit, laufende Betreuung der Kanäle und Kommunikation auf Augenhöhe mit dem Nutzer. Auch wenn ein Twitter Account, eine Facebook Seite oder ein YouTube Kanal auf den ersten Blick „kostenlos“ sind, so muss in das Social Web vor allem eines investiert werden: Zeit. Dabei sollte aber auch nicht vergessen werden, was auch in der klassischen PR gilt: ohne Strategie kein Erfolg.
P8 HOFHERR - Social Media - Ansgar Büngener, Geschäftsführer medienmanufacturP8 Marketing
„Das Social Web hat das Marketing revolutioniert“ so Ansgar Büngener. „Es können heute weltweit 2 Milliarden Internet-Nutzer erreicht werden, die Verbreitung erfolgt in Echtzeit und man kann mit jedem in den Dialog treten.“ Der Schlüssel für einen erfolgreichen Auftritt im Web 2.0 ist Authentizität, Ehrlichkeit, laufende Betreuung der Kanäle und Kommunikation auf Augenhöhe mit dem Nutzer. Auch wenn ein Twitter Account, eine Facebook Seite oder ein YouTube Kanal auf den ersten Blick „kostenlos“ sind, so muss in das Social Web vor allem eines investiert werden: Zeit. Dabei sollte aber auch nicht vergessen werden, was auch in der klassischen PR gilt: ohne Strategie kein Erfolg.
Trailblazing The Immuno-Oncology Frontier Best Companies Of 2024.pdfHealthcareEverything
“Trailblazing The Immuno-Oncology Frontier Best Companies Of 2024” isn’t just a compilation of success stories; it’s a celebration of the triumph of the human spirit over adversity.
1- MarketingBefore putting the product into the market, the prod.docxmonicafrancis71118
1- Marketing
Before putting the product into the market, the product goes through several stages. One of the most important stages is to determine the price of the product. After that, it will be studied by asking questions to customers and anticipate their requirements in terms of shape, colour phrases recorded on it. It can be applied using servery or interview the customer. Finally, the product needs to be promoting before it is been released, so electronic, and visual and audio can be used as advertising. However, in this experiment, we will focus only on the total cost of the product and then work on finding who develops the product….[9] [10].
1.1 Estimating of the total price.
For the antibiotic spray, it can be estimate the total price depend on the type of the material which were be used. Thus, the material in the table estimates the total price.
Material
Discerption
Brand/ manufacture
Price Ink VAT.
[1] Cefuroxime(as Cefuroxime sodium) 1.5 gram.
CEFUROXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections
£4.70
[2] Sterile Water (1000ml)
Single Bottle of Sterile Water (1000ml)
Baxter
£3.54
[3] 73.5 mg of sodium
Sodium Bicarbonate 2kg - Pharmaceutical Grade (Bicarb/Bicarbonate of Soda)
£6.49
[1] Metronidazole
Metronidazole 500mg/100ml infusion 100ml bags (A A H Pharmaceuticals Ltd)
£63.86
[4] Phosphatebuffer (pKa=7.2)
PBS405.1 Virtual PHOSPHATE BUFFERED SALINE pH 7.4 10X Liquid Concentrate, 1L
£22.75
[5] Brilliant Blue FCF
1 kilogram
£6-8
[6] 100ml Stainless Steel
Empty stainless bottle spray
£7-9
Total price
£118
2- Companies and industry
There are many companies interested to work on or collaborate for developing the antibiotic. Following, there are some of the companies, Charities and universities, which they work hardly to improve public health and more specifically in the development of antibiotics. Thus, the product will be a focuses for them and new idea that can be started to develop and prove its effectiveness. Then, it can be put in the market, which many people can take advantage of the ease and licences of the product.
2.1. GSK Company [13]
At GSK, they are at the forefront of researching new ways to tackle some of the world’s biggest healthcare challenges. So as antibiotic resistance grows, they are investing in new ways to fight infection.
Their approach is to make the most of their own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Their vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. They have much to offer and through collaboration, they can achieve so much more.
For example, more than 90% of the vaccines in their pipeline are being developed in partnership with others. They have a long track rec.
The 10 most innovative companies in gene therapyinsightscare
Insights Care has curated a list of “The 10 Most Innovative Companies in Gene Therapy”, we are highlighting the stories of the leading companies that are catalyst to bring this revolutionary change.
Trailblazing The Immuno-Oncology Frontier Best Companies Of 2024.pdfHealthcareEverything
“Trailblazing The Immuno-Oncology Frontier Best Companies Of 2024” isn’t just a compilation of success stories; it’s a celebration of the triumph of the human spirit over adversity.
1- MarketingBefore putting the product into the market, the prod.docxmonicafrancis71118
1- Marketing
Before putting the product into the market, the product goes through several stages. One of the most important stages is to determine the price of the product. After that, it will be studied by asking questions to customers and anticipate their requirements in terms of shape, colour phrases recorded on it. It can be applied using servery or interview the customer. Finally, the product needs to be promoting before it is been released, so electronic, and visual and audio can be used as advertising. However, in this experiment, we will focus only on the total cost of the product and then work on finding who develops the product….[9] [10].
1.1 Estimating of the total price.
For the antibiotic spray, it can be estimate the total price depend on the type of the material which were be used. Thus, the material in the table estimates the total price.
Material
Discerption
Brand/ manufacture
Price Ink VAT.
[1] Cefuroxime(as Cefuroxime sodium) 1.5 gram.
CEFUROXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections
£4.70
[2] Sterile Water (1000ml)
Single Bottle of Sterile Water (1000ml)
Baxter
£3.54
[3] 73.5 mg of sodium
Sodium Bicarbonate 2kg - Pharmaceutical Grade (Bicarb/Bicarbonate of Soda)
£6.49
[1] Metronidazole
Metronidazole 500mg/100ml infusion 100ml bags (A A H Pharmaceuticals Ltd)
£63.86
[4] Phosphatebuffer (pKa=7.2)
PBS405.1 Virtual PHOSPHATE BUFFERED SALINE pH 7.4 10X Liquid Concentrate, 1L
£22.75
[5] Brilliant Blue FCF
1 kilogram
£6-8
[6] 100ml Stainless Steel
Empty stainless bottle spray
£7-9
Total price
£118
2- Companies and industry
There are many companies interested to work on or collaborate for developing the antibiotic. Following, there are some of the companies, Charities and universities, which they work hardly to improve public health and more specifically in the development of antibiotics. Thus, the product will be a focuses for them and new idea that can be started to develop and prove its effectiveness. Then, it can be put in the market, which many people can take advantage of the ease and licences of the product.
2.1. GSK Company [13]
At GSK, they are at the forefront of researching new ways to tackle some of the world’s biggest healthcare challenges. So as antibiotic resistance grows, they are investing in new ways to fight infection.
Their approach is to make the most of their own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Their vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. They have much to offer and through collaboration, they can achieve so much more.
For example, more than 90% of the vaccines in their pipeline are being developed in partnership with others. They have a long track rec.
The 10 most innovative companies in gene therapyinsightscare
Insights Care has curated a list of “The 10 Most Innovative Companies in Gene Therapy”, we are highlighting the stories of the leading companies that are catalyst to bring this revolutionary change.
4th annual Pharma Anti-Counterfeiting 2015Dinesh T
4th Annual Pharma Anti-Counterfeiting 2015 taking place on 08th & 09th September 2015, London, UK
Please contact me :-Dinesh:- dinesh@virtueinsight.co.in
10 Most Trusted Infectious Disease Solution Providers in 2022.pdfinsightscare
In this special edition of our publication, we shine a spotlight on the crucial role of Infectious Disease Solution Providers in empowering health and defeating infections.
10 Most In-Demand Anti-Infective Medicine Brands of 2023.pdfinsightscare
Insights Care’s latest edition, 10 Most In-Demand Anti-Infective Medicine Brands of 2023, provides an overview of the importance of in-demand anti-infective medicine brands in promoting a life of wellness.
This free online book describes how Information Therapy - the right information for the right patient at the right time, can help to heal a sick healthcare system. Patients who have been empowered with Information Therapy are our largest untapped healthcare resource !
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Αντιλήψεις Καθηγητών Πληροφορικής για το φαινόμενο του Διαδικτυακού Εκφοβισμού στην Εκπαιδευτική Πραγματικότητα
Η εκπαίδευση στην εποχή των Τ.Π.Ε
Προσεγγίσεις της εκπαίδευσης μέσα
από την ψηφιακή διάσταση
Αθήνα, 19-20/10/2013
http://synedrio1.com/2013/index.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Venturistas niki pharma
1. VENTURISTAS
Gregory Davrazos
Educational Technology, ICT in Education
Xanthippi Lemontzoglou
Management, Operational Research, Engineering
Yiannis E. Troulis
Business Consulting
Finance, Int’l Business, Marketing, Innovation
2. The Idea
It is about cancer patients who take medication for
cancer. It is about a spin off -“NIKI Pharma”- that will
operate as an immunotherapy and/or biotherapy plant
originated anticancer drug company. We will produce
and market a family of anti-cancer drugs that are based
on plant-derived substances, named NIKI (NIKI in Greek
means Victory).
Unlike the current drugs our products, apart from being
of plant origin drugs, will have the same effectiveness as
the current anti-cancer drugs but with less & fewer side
effects.